ALSO NOTED: Neuromed raises $25M; MS sufferers plead for Tysabri; Emisphere inks deal with Novartis; and much more...

Neuromed Pharmaceuticals, a biopharmaceutical company developing chronic pain drugs, announced the completion of a series D financing of $25 million. This fourth round of financing brings Neuromed's cumulative venture capital financing to $74 million. Release

About two dozen MS sufferers made fervent pleas to an FDA committee to return Tysabri to the market. Report

Emisphere Technologies inked a deal with Novartis worth up to $30 million in milestone payments for the use of its drug delivery technology. Report

Ikonisys has closed a $10 million series D private equity financing round. Release

The jury in the latest Vioxx trial got a close look at Merck documents outlining the company's concerns about the cardiovascular risks posed by the drug long before it was removed from the market. Report

Speedel announced today that it has reached late-stage preclinical profiling of a new series of renin inhibitors designated as the SPP1100 series. Release

Valeant Pharmaceuticals has settled a dispute with the Serbian government. Release

FEI Company and Sweden-based Sidec Technologies today announced that the two companies will collaborate on the commercialization of Protein Tomography solutions and services based on Sidec's proprietary software and intellectual property, and FEI's transmission electron microscopes. Release

And Finally... A new study indicates that physicians' choice of chemotherapy drugs is influenced by payment methods. Article